Identifying Gaps and Providing Recommendations to Address Shortcomings in the Investigation of Acne Sequelae by the Personalising Acne: Consensus of Experts Panel

Overview

Journal JAAD Int

Specialty Dermatology

Date 2021 Nov 24

PMID 34816133

Citations 5

Authors

Alison Layton

Andrew Alexis

Hilary Baldwin

Stefan Beissert

Vincenzo Bettoli

James Del Rosso

Brigitte Dreno

Linda Stein Gold

Julie Harper

Charles Lynde

Diane Thiboutot

Jonathan Weiss

Jerry Tan

Affiliations

Soon will be listed here.

Abstract

Background: The physical sequelae of acne include erythema, hyperpigmentation, and scarring, which are highly burdensome for patients. Early, effective treatment can potentially limit and prevent sequelae development, but there is a need for guidance for and evidence of prevention-oriented management to improve patient outcomes.

Objective: To identify unmet needs of acne sequelae and generate expert recommendations to address gaps in clinical guidance.

Methods: The Personalizing Acne: Consensus of Experts panel of 13 dermatologists used a modified Delphi approach to achieve a consensus on the clinical aspects of acne sequelae. A consensus was defined as ≥75% of the dermatologists voting "agree" or "strongly agree." All voting was electronic and blinded.

Results: The panel identified gaps in current guidance and made recommendations related to acne sequelae. These included identification and classification of sequelae, pertinent points to consider for patient consultations, and management aimed at reducing the development of sequelae.

Limitations: The recommendations are based on expert opinion and made in the absence of high-quality evidence.

Conclusions: The identified gaps should help inform future research and guideline development for acne sequelae. The consensus-based recommendations should also support the process of consultations throughout the patient journey, helping to reduce the development and burden of acne sequelae through improved risk factor recognition, early discussion, and appropriate management.

Citing Articles

Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other Retinoids.

Issa N, Alexis A, Baldwin H, Hamzavi I, Hebert A, Kwong P Dermatol Ther (Heidelb). 2025; 15(3):563-577.

PMID: 39984798 DOI: 10.1007/s13555-025-01344-y.

A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board.

Annunziata M, Barbareschi M, Bettoli V, dallOglio F, Micali G, Monfrecola G Dermatol Ther (Heidelb). 2025; 15(2):245-264.

PMID: 39786713 PMC: 11832873. DOI: 10.1007/s13555-024-01329-3.

What's New After NICE Acne Guidelines.

Layton A, Gupta G, Seukeran D, Maruthappu T, Gaillard S, Whitehouse H Dermatol Ther (Heidelb). 2024; 14(10):2727-2738.

PMID: 39305432 PMC: 11480286. DOI: 10.1007/s13555-024-01275-0.

The Personalized Acne Treatment Tool - Recommendations to facilitate a patient-centered approach to acne management from the Personalizing Acne: Consensus of Experts.

Layton A, Alexis A, Baldwin H, Bettoli V, Del Rosso J, Dirschka T JAAD Int. 2023; 12:60-69.

PMID: 37274381 PMC: 10236180. DOI: 10.1016/j.jdin.2023.03.013.

Management of Acne Vulgaris With Trifarotene.

Tan J, Chavda R, Baldwin H, Dreno B J Cutan Med Surg. 2023; 27(4):368-374.

PMID: 36927117 PMC: 10486177. DOI: 10.1177/12034754231163542.

References

F Alexis A, Harper J, Stein Gold L, Tan J . Treating Acne in Patients With Skin of Color. Semin Cutan Med Surg. 2018; 37(3S):S71-S73. DOI: 10.12788/j.sder.2018.027. View

Layton A, Dreno B, Finlay A, Thiboutot D, Kang S, Lozada V . New Patient-Oriented Tools for Assessing Atrophic Acne Scarring. Dermatol Ther (Heidelb). 2016; 6(2):219-33. PMC: 4906116. DOI: 10.1007/s13555-016-0098-5. View

Davis E, Callender V . A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010; 3(4):24-38. PMC: 2921746. View

Dreno B, Gollnick H, Kang S, Thiboutot D, Bettoli V, Torres V . Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015; 29 Suppl 4:3-11. DOI: 10.1111/jdv.13190. View

Tan J, Tanghetti E, Baldwin H, Gold L, Lain E . The Role of Topical Retinoids in Prevention and Treatment of Atrophic Acne Scarring: Understanding the Importance of Early Effective Treatment. J Drugs Dermatol. 2019; 18(3):255-260. View

Akinboro A, Ezejiofor O, Olanrewaju F, Oripelaye M, Olabode O, Ayodele O . The impact of acne and facial post-inflammatory hyperpigmentation on quality of life and self-esteem of newly admitted Nigerian undergraduates. Clin Cosmet Investig Dermatol. 2018; 11:245-252. PMC: 5955012. DOI: 10.2147/CCID.S158129. View

Connolly D, Vu H, Mariwalla K, Saedi N . Acne Scarring-Pathogenesis, Evaluation, and Treatment Options. J Clin Aesthet Dermatol. 2018; 10(9):12-23. PMC: 5749614. View

Darji K, Varade R, West D, Armbrecht E, Guo M . Psychosocial Impact of Postinflammatory Hyperpigmentation in Patients with Acne Vulgaris. J Clin Aesthet Dermatol. 2017; 10(5):18-23. PMC: 5479473. View

Asai Y, Tan J, Baibergenova A, Barankin B, Cochrane C, Humphrey S . Canadian Clinical Practice Guidelines for Rosacea. J Cutan Med Surg. 2016; 20(5):432-45. DOI: 10.1177/1203475416650427. View

10.

Tan J, Kang S, Leyden J . Prevalence and Risk Factors of Acne Scarring Among Patients Consulting Dermatologists in the USA. J Drugs Dermatol. 2017; 16(2):97-102. View

11.

Carlavan I, Bertino B, Rivier M, Martel P, Bourdes V, Motte M . Atrophic scar formation in patients with acne involves long-acting immune responses with plasma cells and alteration of sebaceous glands. Br J Dermatol. 2018; 179(4):906-917. DOI: 10.1111/bjd.16680. View

12.

Rocha M, Costa C, Bagatin E . Acne vulgaris: an inflammatory disease even before the onset of clinical lesions. Inflamm Allergy Drug Targets. 2014; 13(3):162-7. DOI: 10.2174/1871528113666140606110024. View

13.

Loss M, Leung S, Chien A, Kerrouche N, Fischer A, Kang S . Adapalene 0.3% Gel Shows Efficacy for the Treatment of Atrophic Acne Scars. Dermatol Ther (Heidelb). 2018; 8(2):245-257. PMC: 6002315. DOI: 10.1007/s13555-018-0231-8. View

14.

W Marson J, Baldwin H . New Concepts, Concerns, and Creations in Acne. Dermatol Clin. 2018; 37(1):1-9. DOI: 10.1016/j.det.2018.07.002. View

15.

Desai S . Hyperpigmentation therapy: a review. J Clin Aesthet Dermatol. 2014; 7(8):13-7. PMC: 4142815. View

16.

Hayashi N, Miyachi Y, Kawashima M . Prevalence of scars and "mini-scars", and their impact on quality of life in Japanese patients with acne. J Dermatol. 2015; 42(7):690-6. DOI: 10.1111/1346-8138.12885. View

17.

Kang S, Lozada V, Bettoli V, Tan J, Rueda M, Layton A . New Atrophic Acne Scar Classification: Reliability of Assessments Based on Size, Shape, and Number. J Drugs Dermatol. 2016; 15(6):693-702. View

18.

Abad-Casintahan F, Chow S, Goh C, Kubba R, Hayashi N, Noppakun N . Frequency and characteristics of acne-related post-inflammatory hyperpigmentation. J Dermatol. 2016; 43(7):826-8. DOI: 10.1111/1346-8138.13263. View

19.

Dreno B, Tan J, Kang S, Rueda M, Lozada V, Bettoli V . How People with Facial Acne Scars are Perceived in Society: an Online Survey. Dermatol Ther (Heidelb). 2016; 6(2):207-18. PMC: 4906107. DOI: 10.1007/s13555-016-0113-x. View

20.

Boen M, Jacob C . A Review and Update of Treatment Options Using the Acne Scar Classification System. Dermatol Surg. 2019; 45(3):411-422. DOI: 10.1097/DSS.0000000000001765. View